BIMASTAT 150 + 25 MG/ML ORAL SUSPENSION

국가: 사이프러스

언어: 그리스어

출처: Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

유효 성분:

SULFADIAZINE; NEOMYCIN SULFATE

제공처:

PANCHRIS FEEDS (VETERINARY) LTD (0000003032) INDUSTRIAL ZONE ARADIPPOU, 7100 LARNACA, P O BOX 40261

ATC 코드:

QJ01RA02

INN (International Name):

SULFONAMIDES, COMB WITH OTHER ANTIBACTERIALS EXCL TRIMETHOPRIM

복용량:

150 + 25 MG/ML

약제 형태:

ORAL SUSPENSION

구성:

SULFADIAZINE (0000068359) 150MG; NEOMYCIN SULFATE (0001405103) 25MG

관리 경로:

ORAL USE

처방전 유형:

Εθνική Διαδικασία

치료 영역:

SULFONAMIDES, COMB WITH OTHER ANTIBACTERIALS EXCL TRIMETHOPRIM

제품 요약:

Νομικό καθεστώς: Με Ιατρική Συνταγή; VIAL X 250 ML (20V037301) 250 MILLILITRE - Εγκεκριμένο - Με Ιατρική Συνταγή

환자 정보 전단

ΠΑΡΑΡΤΗΜΑ 2: ΦΥΛΛΟ ΟΔΗΓΙΩΝ ΧΡΗΣΗΣ
Το προϊόν αυτό, δεν έχει φύλλο οδηγιών
χρήσης. Όλες οι πληροφορίες
αναγράφονται στην
στοιχειώδη συσκευασία.
1/1

제품 특성 요약

ΠΑΡΑΡΤΗΜΑ 1: ΠΕΡΙΛΗΨΗ ΤΩΝ
ΧΑΡΑΚΤΗΡΙΣΤΙΚΩΝ ΤΟΥ ΠΡΟΪΟΝΤΟΣ
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Bimastat
Oral Suspension for pre-ruminant calves
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE SUBSTANCES:
Sulfadiazine
150 mg/ml
Neomycin (as neomycin sulphate)
25 mg/ml
EXCIPIENTS:
Methyl parahydroxybenzoate
2.0 mg/ml
Propyl parahydroxybenzoate
0.2 mg/ml
Carmoisine E122
0.05 mg/ml
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Oral suspension.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Pre-ruminant calves.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of diarrhoea in pre-ruminant calves associated with
infections caused by organisms known to be, or suspected of being,
susceptible to the combination of sulfadiazine and neomycin.
4.3
CONTRAINDICATIONS
Do not use in animals with know hypersensitivity to the active
ingredient.
Do not exceed the recommended dosage or the period of treatment.
Do not use local anesthetics of the procaine group during treatment as
they
are antagonistic to the sulphonamide component.
Do not use in calves with functional rumens.
Do not use in lactating cows.
Do not use in foals and horses.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Concurrent intravenous fluid therapy should be considered in
dehydrated
calves. Parenteral antibiotic treatment should be considered if a
clinical
response is not seen after 48 hours treatment.
1/4
4.5
SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Use of the product should be based on susceptibility testing of the
bacteria
isolated from the animal. If this is not possible, therapy should be
based on
local (regional, farm level) epidemiological information about
susceptibility of
the target bacteria.
SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE
VETERINARY MEDICINAL PRODUCT TO ANIMALS
Avoid contact with skin.
Wash hands after use.
4.6
ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
Chronic usage of oral neomycin may result